Other OTC - Delayed Quote USD

National Graphite Corp. (NGRC)

0.0680 0.0000 (0.00%)
As of April 15 at 12:08 PM EDT. Market Open.
Loading Chart for NGRC
DELL
  • Previous Close 0.0680
  • Open 0.1240
  • Bid --
  • Ask --
  • Day's Range 0.0680 - 0.0680
  • 52 Week Range 0.0380 - 0.1240
  • Volume 19
  • Avg. Volume 1,475
  • Market Cap (intraday) 10.493M
  • Beta (5Y Monthly) -2.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.

--

Full Time Employees

May 31

Fiscal Year Ends

Related News

Performance Overview: NGRC

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NGRC
30.77%
S&P 500
6.11%

1-Year Return

NGRC
17.24%
S&P 500
22.44%

3-Year Return

NGRC
56.69%
S&P 500
22.40%

5-Year Return

NGRC
54.55%
S&P 500
74.05%

Compare To: NGRC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NGRC

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -2.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -7,580.21%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -1.97M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.17k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.31M

Company Insights: NGRC

People Also Watch